Raymond A. Rubin

5.2k total citations · 2 hit papers
44 papers, 2.0k citations indexed

About

Raymond A. Rubin is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Raymond A. Rubin has authored 44 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hepatology, 22 papers in Epidemiology and 12 papers in Surgery. Recurrent topics in Raymond A. Rubin's work include Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (14 papers) and Liver Disease and Transplantation (12 papers). Raymond A. Rubin is often cited by papers focused on Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (14 papers) and Liver Disease and Transplantation (12 papers). Raymond A. Rubin collaborates with scholars based in United States, Canada and Spain. Raymond A. Rubin's co-authors include Steven K. Herrine, Ziv J. Haskal, Clifford A. Brass, Constantin Cope, Ira M. Jacobson, John M. Vierling, Paul Y. Kwo, Jonathan McCone, Natarajan Ravendhran and Lorenzo Rossaro and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Raymond A. Rubin

43 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2010 515 citations Paul Y. Kwo, Eric Lawitz et al. The Lancet profile →
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome

2021 246 citations K. Rajender Reddy, Raymond A. Rubin et al. profile →

Peers

Countries citing papers authored by Raymond A. Rubin

Since Specialization

Citations

This map shows the geographic impact of Raymond A. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond A. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond A. Rubin more than expected).

Fields of papers citing papers by Raymond A. Rubin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond A. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond A. Rubin. The network helps show where Raymond A. Rubin may publish in the future.

Co-authorship network of co-authors of Raymond A. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond A. Rubin. A scholar is included among the top collaborators of Raymond A. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond A. Rubin. Raymond A. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disparities in Access to Liver Transplant Referral and Evaluation among Patients with Hepatocellular Carcinoma in Georgia 2024 ·Cancer Research Communications ·(unknown), (unknown), Raymond Lynch, Lauren E. McCullough, (unknown), Lauren Nephew, Jonathan Hundley, Raymond A. Rubin, Rachel E. Patzer	4
2	Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population 2024 ·Liver Transplantation ·K. Rajender Reddy, Ethan M. Weinberg, Stevan A. Gonzalez, Manhal Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Zachary Fricker, (unknown), (unknown), (unknown), (unknown), Amy Olofson, (unknown), (unknown), Het Patel, (unknown), (unknown), (unknown), Khurram Jamil	2
3	INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion 2023 ·Contemporary Clinical Trials Communications ·Ethan M. Weinberg, (unknown), Stevan A. Gonzalez, Manhal Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, (unknown), (unknown), (unknown), (unknown), (unknown), Khurram Jamil, Zachary Fricker, K. Rajender Reddy	1
4	Safety and efficacy of continuous infusion terlipressin in acute kidney injury-hepatorenal syndrome: the Infuse study 2023 ·Journal of Hepatology ·K. Rajender Reddy, Ethan M. Weinberg, Stevan A. Gonzalez, Manhal Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Zachary Fricker, (unknown), (unknown), (unknown), Khurram Jamil	1
5	End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis 2019 ·CardioVascular and Interventional Radiology ·J. Titano, A. Fischman, (unknown), (unknown), Lance L. Stein, (unknown), Raymond A. Rubin, (unknown), (unknown), (unknown), (unknown), Aravind Arepally	17
6	Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo 2018 ·Clinical Gastroenterology and Hepatology ·Catherine Frenette, Giuseppe Morelli, Mitchell L. Shiffman, R. Todd Frederick, Raymond A. Rubin, Michael B. Fallon, (unknown), Matt Cave, Saira Khaderi, Omar Massoud, Nikolaos Pyrsopoulos, James Park, James M. Robinson, Mason Yamashita, Alfred P. Spada, Jean L. Chan, David Hagerty	75
7	Donor-Derived Hepatic Neuroendocrine Tumor: Pause Before Proceeding With Liver Retransplantation 2016 ·Transplantation Direct ·(unknown), Lance L. Stein, Roshan Shrestha, Devina Bhasin, Steven J. Citron, Raymond A. Rubin	1
8	Randomised clinical trial: pre‐dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment‐naïve patients with chronic hepatitis C genotype 1 2012 ·Alimentary Pharmacology & Therapeutics ·Melissa Palmer, Raymond A. Rubin, Vinod K. Rustgi, (unknown)	4
9	Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial breakdown → 2010 ·The Lancet ·Paul Y. Kwo, Eric Lawitz, Jonathan McCone, Eugene R. Schiff, John M. Vierling, David Pound, Mitchell Davis, Joseph Galati, Stuart C. Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Frank Anderson, Ira M. Jacobson, Raymond A. Rubin, Kenneth Koury, Lisa D. Pedicone, Clifford A. Brass, Eirum Chaudhri, Janice K. Albrecht	515
10	Noncirrhotic Portal Hypertension in Patients With Human Immunodeficiency Virus–1 Infection 2008 ·Clinical Gastroenterology and Hepatology ·(unknown), (unknown), (unknown), Roshan Shrestha, Mark W. Johnson, Marty T. Sellers, Michael Galambos, Raymond A. Rubin	53
11	[626] PRE-DOSING TARIBAVIRIN PRIOR TO COMBINATION THERAPY WITH PEGYLATED INTERFERON ALFA-2b VERSUS STANDARD COMBINATION DOSING: 24-WEEK INTERIM RESULTS EXAMINING SAFETY AND VIRAL KINETICS 2007 ·Journal of Hepatology ·Megan Palmer, Raymond A. Rubin, V. Rustgi, (unknown), (unknown)	1
12	Terbinafine-induced hepatic failure requiring liver transplantation 2006 ·Liver Transplantation ·(unknown), Mark W. Johnson, Raymond A. Rubin, (unknown), Carlos Zayas, (unknown), (unknown), Kimberly Thomas, (unknown), Roshan Shrestha	35
13	Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C 2004 ·Journal of Viral Hepatitis ·Robert Perrillo, Kenneth D. Rothstein, Raymond A. Rubin, (unknown), Joanne C. Imperial, (unknown), Sylvia Hu, Winslow Klaskala	43
14	Clinical significance of pegylated interferon induced neutropenia: Results from the WIN-R trial 2003 ·Gastroenterology ·Furqaan Ahmed, Ira M. Jacobson, Robert S. Brown, Nezam H. Afdhal, Raymond A. Rubin, James R. Spivey, Bradley Freilich, Fredric Regenstein, David Bernstein, (unknown), Clifford A. Brass	5
15	EVALUATION OF THE SOLID HEPATIC MASS 1996 ·Medical Clinics of North America ·Raymond A. Rubin, Donald G. Mitchell	21
16	FatalVibrio parahemolyticus septicemia in a patient with cirrhosis 1995 ·Digestive Diseases and Sciences ·(unknown), Raymond A. Rubin, Henry Fraimow, Margaret Hoffman-Terry	18
17	Nuclear imaging of solid hepatic masses 1995 ·Seminars in Roentgenology ·Margaret Kinnard, Abass Alavi, Raymond A. Rubin, Gary R. Lichtenstein	13
18	Intestinal varices: treatment with the transjugular intrahepatic portosystemic shunt. 1994 ·Radiology ·Ziv J. Haskal, Mark D. Scott, Raymond A. Rubin, Constantin Cope	86
19	Hepatic arterial injury after transjugular intrahepatic portosystemic shunt placement: report of two cases. 1993 ·Radiology ·Ziv J. Haskal, Michael J. Pentecost, Raymond A. Rubin	63
20	Acute esophageal obstruction: a unique presentation of a giant intramural esophageal leiomyoma. 1992 ·PubMed ·Raymond A. Rubin, Gary Lichtenstein, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact